Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 10.31M P/E - EPS this Y 60.50% Ern Qtrly Grth -
Income -37.03M Forward P/E -1.54 EPS next Y 36.40% 50D Avg Chg -5.00%
Sales 443k PEG - EPS past 5Y - 200D Avg Chg -43.00%
Dividend N/A Price/Book 0.83 EPS next 5Y - 52W High Chg -85.00%
Recommedations 2.00 Quick Ratio 3.14 Shares Outstanding 852.93K 52W Low Chg 62.00%
Insider Own 0.79% ROA -71.51% Shares Float 844.46K Beta 1.02
Inst Own 8.78% ROE - Shares Shorted/Prior 59.36K/16.17K Price 0.94
Gross Margin -271.78% Profit Margin - Avg. Volume 2,961,535 Target Price 100.00
Oper. Margin -2,000.92% Earnings Date Nov 12 Volume 179,408 Change -2.49%
About Trevena, Inc.

Trevena, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel medicines for patients affected by central nervous system disorders. Its lead product candidates include OLINVYK (Oliceridine) injection, a G protein biased mu-opioid receptor (MOR) ligand for the management of moderate-to-severe acute pain; TRV734, a small molecule G protein biased ligand of the MOR, which has completed phase I studies for the treatment of moderate-to-severe acute and chronic pain; and TRV045, a novel S1P modulator for managing chronic pain. Trevena, Inc. was incorporated in 2007 and is headquartered in Chesterbrook, Pennsylvania.

Trevena, Inc. News
11/07/24 Trevena: Q3 Earnings Snapshot
11/07/24 Trevena Reports Third Quarter 2024 Results and Provides Business Update
10/04/24 Trevena Announces Receipt of Nasdaq Delisting Notification
08/12/24 Upcoming Stock Splits This Week (August 12 to August 16) – Stay Invested
08/08/24 Trevena Announces Reverse Stock Split
08/08/24 Trevena: Q2 Earnings Snapshot
08/08/24 Trevena Reports Second Quarter 2024 Results and Provides Business Update
08/01/24 Sagimet Biosciences Announces Appointment of Anne Phillips and Jennifer Jarrett to its Board of Directors
07/08/24 Trevena Announces $2M Non-Dilutive Financing Tranche and Reduction in Outstanding Liabilities in Connection with Existing ex-US Royalty Financing
06/20/24 Trevena Announces Preclinical TRV045 Data Providing Insight Into Novel Mechanism of Analgesic Effect in Chronic Neuropathic Pain Model and Demonstrating Statistically Significant Anti-Seizure Activity in Epilepsy Models
05/15/24 Trevena Reports First Quarter 2024 Results and Provides Business Update
04/01/24 Trevena Reports Fourth Quarter 2023 Results and Provides Corporate Update
12/28/23 Trevena Announces the Closing of $4 Million Concurrent Private Placement and Warrant Exercise
12/27/23 Trevena Inc. Announces $4 Million Concurrent Private Placement and Warrant Exercise
12/04/23 Trevena Announces TRV045 Presentation at the American College of Neuropsychopharmacology 62nd Annual Meeting
12/04/23 Trevena Awarded OLINVYK Agreement with Premier, Inc.
11/30/23 Trevena Announces Acceptance of Abstract Examining the Use of OLINVYK in Patients with Acute Burn Injuries
TRVN Chatroom

User Image blonde_on_blonde Posted - 1 day ago

$TRVN So Nhwa in China sold about $3M in Olinvyk last quarter. Our goofball management team lost $20k trying to sell Olinvyk last quarter in the US. The current market cap is only $1.5M and the company is no longer tied to management salaries. I know they have some seriously f*cked up loans to pay off, but I don't think the sales in China are going to go down over time. Maybe I am way off base, but I think Olinvyk can be sold in the US with the right team in place. Hard to imagine how dumb dumb Carrie can't sell this company.

User Image Market77 Posted - 2 days ago

$TRVN

User Image iiivid Posted - 5 days ago

$TRVN another 5% acquisitions today, wtf going on here 🤷‍♂️

User Image blonde_on_blonde Posted - 6 days ago

$TRVN checking in on this sad stock... Looks like Q3 US revenue -$21k and revenue from China license +$304k? I can't remember the percentage for China sales but this would indicate the NIWA (forgot company) is selling a shit load of Oli and it's not just one quarter now.

User Image iiivid Posted - 6 days ago

$TRVN downgraded to hold from buy finally, so it will be rocketing soon 😂👌

User Image End00Game Posted - 1 week ago

$TRVN wow, I recall buying $30k of shares just days before failed PDUFA at FDA. It took almost 3 years and cost averaging down to recover but I did get a 5x return many months after OLI approval the summer following covid. Had fun learning about biotechnology from many here in the forum over the years.

User Image SpencerF Posted - 1 week ago

$TRVN just checking in, this one a for sure good one to dump? Or still a chance something could come from it?

User Image armando5908 Posted - 1 week ago

$TRVN Everyone is taking their pennies out. Oct-08-2024 BOURDOW, CARRIE L. Chief Executive Officer Disposition (Non Open Market) 1,822 $1.47 2.7K 23,894 Oct-08-2024 DEMITRACK, MARK Officer Disposition (Non Open Market) 885 $1.47 1.3K 11,363 Oct-08-2024 SHIN, BARRY Chief Financial Officer Disposition (Non Open Market) 806 $1.47 1.2K 11,543 Sep-14-2024 YODER, ROBERT T. Senior Vice President Disposition (Non Open Market) 487 $5.95 2.9K 5,868 Sep-14-2024 SHIN, BARRY Chief Financial Officer Disposition (Non Open Market) 3 $5.95 17.9 12,349 1

User Image Inspector510 Posted - 1 week ago

$TRVN Have a wonderful weekend!! God bless all of you!!!….

User Image iiivid Posted - 1 week ago

$TRVN as i said before, i wouldn’t share billions with fucking retailers if i were to invent Oli which to end 100 years of monopoly of morphin 😂👍

User Image perchedcats Posted - 1 week ago

$TRVN maybe a CNS player in the epilepsy space will buy this for peanuts (045) Xene? they have acqui assets in the past… their lead drug (in ph3) for example

User Image iiivid Posted - 1 week ago

$TRVN all ready, who gonna buy it, that is the only question, Pfizer or Johson&Johson 🤷‍♂️

User Image perchedcats Posted - 1 week ago

$TRVN so they fired the c-suite including Carrie but shes still acting https://www.fiercebiotech.com/biotech/trevena-teeters-dangerous-territory-terminating-ceo-and-other-execs-amid-strategic-review

User Image bbcontroll Posted - 2 weeks ago

$TRVN this sh.t shows $15+ cash/sh. The problem the sales. I cannot believe that nobody could sell the Olinvyk ptoduct. 🤦🤌🤌

User Image armando5908 Posted - 2 weeks ago

$TRVN funny to see all the idiots posting bullish for this sad, sad scam.

User Image PharmaExpert Posted - 2 weeks ago

$AKBA, $ARDX, $SONN, $RKDA, $TRVN 🔥🔥🔥🔥🔥

User Image bbcontroll Posted - 2 weeks ago

$TRVN Do you have any info related to this s.it?

User Image M592018 Posted - 2 weeks ago

$TRVN

User Image iiivid Posted - 10/30/24

$TRVN u can buy now at Webull 👍🕺

User Image Artie_11 Posted - 10/30/24

$TRVN *coughs*

User Image Shooter40 Posted - 10/29/24

$TRVN I wonder if king_of_cars still expects to make a lot of money with Carrie at the helm after two 1 for 25 reverse splits?

User Image Mnpois Posted - 10/28/24

$TRVN why is this still around

User Image AZOZ Posted - 10/28/24

$TRVN oversold On watch for possible reversal soon!

User Image Estimize Posted - 10/28/24

Wall St is expecting -100.00% YoY revenue growth for $TRVN in Q3, down from -89.24% in Q2 [Reporting 11/05 BMO] http://www.estimize.com/int

User Image Cornishpasty Posted - 10/24/24

$TRVN good gains ! Now join us at $XXII , only FDA product on the market! For low nicotine cigarettes and at $0.10 a share !

User Image N1010 Posted - 10/24/24

$TRVN look at MRNS chart not just today but across the last year. Of course the Marinus ( mrns ) ceo is on the Trevena board.

User Image iiivid Posted - 10/23/24

$TRVN very interesting. Most promising is TRVN it says 😂🤷‍♂️ https://www.pharmaceutical-technology.com/analyst-comment/opioid-addiction-8mm-2033/?cf-view

User Image perchedcats Posted - 4 weeks ago

@iiivid yeah $LBTH second drug candidate m is exactly what $TRVN 045 is but this management team are useless

User Image iiivid Posted - 1 month ago

$TRVN could be DRUG, even better but CEO choose to fuck investors instead 😂🤷‍♂️

User Image AlertsAndNews Posted - 1 month ago

$TRVN highs and with volume

Analyst Ratings
HC Wainwright & Co. Buy May 16, 24
HC Wainwright & Co. Buy Apr 2, 24
HC Wainwright & Co. Buy Mar 11, 24
JMP Securities Market Outperform May 17, 23
JMP Securities Market Outperform Mar 31, 23
HC Wainwright & Co. Buy Mar 31, 23
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
Shin Barry SVP, CFO SVP, CFO Jun 28 Sell 0.41 31,785 13,032 873,056 06/29/22